31 Effective, Affordable, And Highly Rated Beauty Items
According to the Cleveland Clinic, some researchers have found rosemary oil to be as effective at encouraging hair growth as Rogaine! And read more about how biotin could help with the fullness of hair at Cleveland Clinic.
Promising reviews: "Legit magic in a bottle. Wish I could order this stuff by the gallon. Took a chance on this because I was desperate, having already spent so much money on luxury and drugstore products with little results. I use this as a pre-treatment on scalp and ends before I wash hair. Scalp has improved dramatically. I feel like there's not as much breakage/fallout, and my ends are fuller. (This is after like six months, but my scalp was better immediately.)" —Claire Blanchard
I hardly write reviews but this one deserves to be written about!! My hair was falling out a LOT, and somehow just with the FIRST application onwards, I started seeing less fall. And now, after four months, I can see hair growth as well, and my hair is already looking thicker!! And I've been using it only once a week, just a few drops and massaging in. Omg, how can anything be so simple and yet so effective!!! Amazing! Amazing!!! Whoever invented this, hats off!!" —Dee
Get it from Amazon for $9.97
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
7 hours ago
- Health Line
Ask the Expert: Should I have Biomarker Testing – and Would it Help?
Biomarker testing in colorectal cancer can help assess inherited risk and identify characteristics that may influence the disease's growth, spread, and response to treatment. Colorectal cancer (CRC) starts in the colon or rectum of the large intestine. Your doctor may refer to it as 'colon cancer' or 'rectal cancer,' depending on where the cancer develops first, but both of these diagnoses are included under the banner of CRC. CRC is treatable, and biomarker testing is a part of precision medicine in your comprehensive treatment plan. Biomarker testing in CRC can help detect cancer in its earliest, most treatable stages. It can also provide important details about cancer after a diagnosis that influence treatment and outcomes. Dr. Smitha Krishnamurthi, a gastrointestinal oncology specialist with the Cleveland Clinic, talks with Healthline about biomarker testing and who it's recommended for. What is biomarker testing? Biomarker testing refers to testing of the colorectal cancer to find out if there are certain changes in the cancer's genes and proteins that could impact prognosis [outlook] and treatment. What are the most common biomarkers, and what do they show? Biomarkers in CRC measure a variety of different biological processes and states. Each biomarker provides important details about the cancer's growth, spread, or treatment response. DNA mismatch repair Hospital pathology labs now commonly test all initial biopsies or surgical specimens of colorectal cancer for the presence of DNA mismatch repair proteins. This is done via immunohistochemistry (IHC) staining of the slides to look for [the] expression of four mismatch repair proteins: MLH1, PMS2, MSH2, and MSH6. If one or two of these proteins are missing, then the cancer has deficient DNA mismatch repair. Microsatellite instability (MSI) This is a polymerase chain reaction (PCR) or next-generation sequencing (NGS) test [that looks] for abnormalities in microsatellite regions of the cancer DNA. The test can be done on a tumor specimen or blood (liquid biopsy). Microsatellites are short, repeated sequences of DNA. If the cancer has [atypical] DNA mismatch repair, errors will appear in microsatellite regions of DNA in the form of missing bases or extra bases added to the DNA sequence. RAS gene mutations (mutations in KRAS and NRAS genes) This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). RAS is a very important oncogene, meaning that it is a gene that, when mutated, drives cancer cell proliferation and survival. Mutations in RAS genes are found in up to 50% of colorectal cancers. BRAF V600E gene mutation This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). The BRAF V600E protein can also be detected by IHC. BRAF is another oncogene, so when it is mutated, it leads to cancer cell proliferation and survival. BRAF V600E mutations occur in about 8% to 10% of colorectal cancers and are more common in right-sided cancers. HER2 protein overexpression by IHC or gene amplification by NGS HER2 is another oncogene — gene amplification leads to [the] overexpression of the HER2 protein. Overexpression of HER2 leads to increased signaling via the epidermal growth factor receptor pathway, leading to cancer cell proliferation and survival. PIK3CA PIK3CA is another oncogene. Mutations in PIK3CA and a related gene, PIK3R1, lead to cancer cell proliferation and survival. Mutations in PIK3CA and PIK3R1 are typically found via NGS. PTEN PTEN is a tumor suppressor gene, [which typically] suppresses cancer growth. When the PTEN gene is mutated, the protein is not expressed, and that leads to [the] proliferation of cancer. PTEN gene mutations are typically found via NGS. Who should have biomarker testing done? All patients with colorectal cancer should have testing of their cancer for DNA mismatch repair (or microsatellite instability) soon after diagnosis. This is important for patients with cancers of all stages. Patients with early stage colorectal cancer should have testing of their cancers for mutations in PIK3CA, PTEN, and PIK3R1 by the time they finish adjuvant treatment or after surgery if [they're] not having adjuvant treatment. Patients with metastatic colorectal cancer should have next-generation sequencing of the cancer soon after diagnosis, as the results may impact the initial systemic treatment. The NGS results are also useful for identifying clinical trial eligibility. Comorbidities will not affect the results of these biomarkers, so they should not affect the timing and decision making about ordering these tests. How does biomarker testing help the treatment and outcome of a diagnosis? Biomarkers can impact your treatment choices and outcomes. They can help doctors decide which medications will be the most effective, identify inherited features in cancer, and determine if adjuvant or additional therapies would improve outcomes. Immunotherapy responsiveness It is critical to know if a cancer has deficient DNA mismatch repair (dMMR) or high microsatellite instability (MSI-H) because these cancers can respond dramatically to immunotherapy in the early stage and metastatic settings. For example, patients with rectal cancer that is dMMR or MSI-H may have a complete clinical response with immunotherapy and may be able to avoid radiation and surgery. Thus, this testing needs to be done early, before treatment starts. Identifying Lynch syndrome Another important reason for testing for dMMR or MSI-H is to identify cancers caused by Lynch syndrome. Lynch syndrome is the most common type of inherited colorectal cancer and is caused by germline mutations in the genes that code for the DNA mismatch repair proteins or in another related gene called EPCAM. Most cancers with deficient mismatch repair or MSI-H are not caused by Lynch syndrome and occur sporadically. We don't want to miss patients with Lynch syndrome, however, because they can benefit from counseling about [the] prevention of Lynch syndrome-related cancers such as uterine cancer, ovarian cancer, and gastric cancer, in addition to colorectal cancer. When a patient is diagnosed with Lynch syndrome, family members can then be tested to see if they have Lynch syndrome. Recommendations for cancer screening at early stages are made for individuals with Lynch syndrome, and early screening can be lifesaving. Identifying treatment resistance Mutations in KRAS and NRAS make cancers resistant to anti-epidermal growth factor receptor therapy. Cancers with KRAS G12C mutations can be treated with a regimen that targets this mutation (adagrasib plus cetuximab or sotorasib plus panitumumab). There are also many clinical trials now studying RAS gene inhibitors in patients with metastatic colorectal cancer that have been previously treated. Cancers with BRAF V600E tend to be aggressive and less sensitive to chemotherapy. There is a Food and Drug Administration (FDA)-approved regimen targeting BRAF V600E (encorafenib plus cetuximab) in metastatic colorectal cancer that improves survival when added to first-line FOLFOX chemotherapy. It also improves survival as a second-line treatment after chemotherapy. Greater response to targeted and adjuvant therapy Metastatic colorectal cancers that demonstrate [the] overexpression or gene amplification of HER2 can be treated with a targeted regimen of tucatinib plus trastuzumab after initial chemotherapy. Another targeted treatment available for metastatic colorectal cancers that overexpress HER2 by IHC is trastuzumab deruxtecan. Patients with early stage colorectal cancer with mutations in the PIK3CA, PIK3R1, or PTEN genes should be treated with aspirin 160 milligrams daily for 3 years after adjuvant therapy or after surgery if [they're] not having adjuvant therapy. The ALASCCA trial, presented at ASCO GI [American Society of Clinical Oncology – Gastrointestinal Cancer] in 2025, compared a placebo to aspirin in this patient population and found that aspirin significantly lowered the rate of cancer recurrence at 3 years. This is rather new data. Oncologists are starting to order NGS testing for patients with early stage cancers in order to obtain this biomarker information. What should you ask your doctor? It's always OK to ask your doctor about biomarker testing and what it means for you. Important questions to consider include: Is my cancer dMMR/MSI-H? Am I a candidate for immunotherapy? Patients with early stage colorectal cancer should ask if aspirin therapy will be recommended based on biomarker testing. Patients with metastatic colorectal cancer should ask for the results of RAS/BRAF/HER2 testing and overall NGS testing results.
Yahoo
16 hours ago
- Yahoo
‘She always said, 'I'm going to be famous, dad'': Teen dies after viral TikTok ‘dusting' challenge
The parents of a 19-year-old who dreamed of fame and died after trying the TikTok 'dusting' trend are warning others about its deadly risks. Renna O'Rourke and her boyfriend DoorDashed aerosol keyboard cleaner to her parents' Tempe, Arizona, home without her mother's knowledge, Dana O'Rourke told 12 News. The dusting trend, also known as chroming or huffing, involves inhaling common household cleaners to get high for views online. The sensation causes brief euphoria but can cause instant, fatal damage, often due to heart failure, according to the Cleveland Clinic. After inhaling the keyboard cleaner, Renna went into cardiac arrest, spent a week unconscious in the intensive care unit, and then was declared brain-dead. Renna's parents described their late daughter as 'vivacious and caring and loyal.' Her father, Aaron O'Rourke, told 12 News that Renna loved to sing and lit up every room with her smile and laughter. 'She always said, 'I'm going to be famous, dad. Just you watch. I'm going to be famous,' and unfortunately, this is not under the most optimal of circumstances,' Aaron O'Rourke, told the outlet.. Despite the less-than-ideal circumstances, the O'Rourke family is now working to honor Renna by spreading the word about the dangers of huffing for teens and parents. 'There's no ID required. It's odorless. It's everything kids look for. They can afford it, they can get it, and it doesn't show in mom and dad's drug test,' Dana O'Rourke told AZ Family about access to the trendy chemicals. She added, 'Don't take your kid's word for it. Dig deep. Search their rooms. Don't trust — and that sounds horrible, but it could save their life.' A GoFundMe started to help the O'Rourke family with hospital bills, burial and therapy costs, and to spread awareness about huffing has surpassed its $5,000 goal and sits at over $9,000 at the time of publication.
CNET
a day ago
- CNET
Breathe Easy This Allergy Season With 50% Off a Morento Air Purifier
Springtime is rough for a lot of us with all manner of plant life shooting pollen into the air with reckless abandon. But a good air purifier can help keep allergies at bay, at least within the safety of your own home, and right now you can get your hands on the Morento air purifier while it's 50% off at Amazon. That means it's down to just $80, and it's a great way to clear that air up. Make sure you act fast if you want it though, as there's no telling how long this deal will last. The Morento air purifier -- full name Morento HY4866-WF -- can handle rooms up to 1,076 square feet, which is going to be enough for most bedrooms or living rooms. Along with that, it has an air quality display to help you see how well it's doing, and it even comes with a couple of extra filters. That's just good news for general usability, because we all forget to order new ones the first time around. The result of all of this is that you can get rid of pollutants and allergens in the air, and that can help immensely when you're in the middle of allergy season, or if you've got pets you're suffering with a bit. Hey, did you know? CNET Deals texts are free, easy and save you money. In addition to being generally good at clearing the air, it's also smart, meaning you can control it with Alexa, Google Assistant or the accompanying app so that you can turn it on or off without having to get up or set it to run on a schedule that suits you. Given the power and functionality of this device, not to mention the discount, there's no denying that this is one of the best air purifier deals going on right now. Just make sure you act fast to avoid missing out on it. Why this deal matters A solid air purifier can actually improve some peoples' quality of life a fair bit. The ability to take out things like smoke is good, but the real winner here for many of us is the ability to filter out allergens like pollen and dust. Hayfever season is in full swing at the moment, so being able to save 50% on breathing properly is a great deal.
